| 引用本文:宋培放，潘秋莎，杨凌.药物性肝损伤生物标志物[J].世界中医药,2020,(23):. |
|
| 药物性肝损伤生物标志物 |
| Biomarkers of Drug-induced Liver Injury |
| 投稿时间：2020-11-19 |
| DOI：10.3969/j.issn.1673-7202.2020.23.004 |
| 中文关键词: 生物标志物 药物性肝损伤 急慢性肝病 药物分类 组学 |
| English Keywords:Biomarker Drug-induced liver injury(DILI) Acute and chronic liver disease Drug classification Omics |
| 基金项目:国家重点研发计划项目(2017YFC1702000，2020YFC0845400);国家重大专项“重大新药创制”项目(2018ZX09731016-004);国家自然科学基金项目(81803489,81703604,81903576,81773810) |
|
| 摘要点击次数: 337 |
| 全文下载次数: 0 |
| 中文摘要: |
| 生物标志物是源于机体器官、组织、细胞、亚细胞器中的标志性和(或)功能性分子,可以标记器官、组织、细胞及亚细胞结构或功能的改变。药物性肝损伤(DILI)一般会临床表型几乎涉及所有急慢性肝脏疾病,其发生发展过程的动态监控一直是基础和应用药理学研究领域面临的巨大挑战。除了传统的ALT,ASP,AST等指标外,目前许多新型生物分子作为生物标志物被报道,组学技术的发展也为DILI检测提供了更多的生物标志物分子,本文综述了导致肝损伤的药物类型,并对肝损伤的生物标志物进行综述,为DILI的研究提供选择和指导。 |
| English Summary: |
| Biomarkers are markers or/and functional molecules derived from organs,tissues,cells,and subcellular organelles,which can mark changes in the structure or function of organs,tissues,cells,and subcellular organs.Drug-induced liver injury(DILI)generally involves clinical phenotypes of almost all acute and chronic liver diseases,and dynamic monitoring of its occurrence and development has always been a huge challenge in the field of basic and applied pharmacology.In addition to the traditional ALT,ASP,AST and other indicators,many new biomolecules have been reported as biomarkers.The development of omics technology also provides more biomarker molecules for DILI detection.This paper reviews the drug types that cause liver damage and biomarkers of liver injury,to provide selection and guidance for DILI research. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|
